A Peptide Company Just Set the Record for the Largest Venture-Backed Biotech IPO
Parabilis Medicines' Nasdaq debut, priced at a $670 million offering and closing at $770.5 million, puts a stabilized-peptide platform atop a ranking long ruled by antibody and small-molecule firms.